Proteomic risk score for early prediction of kidney disease progression in individuals with APOL1 high-risk genotypes
Comprehensive Overview
This study, published in Nature Medicine (2026), investigated whether measuring proteins in the blood could predict, years in advance, which people carrying high-risk versions of a particular gene will develop serious kidney problems, since only one in five with this genetic profile progresses to kidney failure and doctors have lacked tools to identify them ahead of time. The gene, APOL1, is carried mainly by people of African ancestry, and its high-risk versions are a major reason kidney failure develops at nearly four times the rate in this population compared with others. Researchers measured thousands of blood proteins in 851 adults of African ancestry carrying these high-risk gene variants who still had normal kidney function at the study's start, drawn from a large Pennsylvania hospital biobank. From these measurements, they built a nine-protein blood test, called a proteomic risk score, combined with basic clinical information to predict who would experience major kidney decline, kidney failure, or death over the following years. Researchers then compared this new score against existing prediction tools, including a clinical calculator and genetic risk scores, in the original group and two separate patient cohorts. The new blood test substantially outperformed every existing tool at identifying at-risk patients.
Outcomes and Implications
The most striking finding was the sheer size of the gap in risk the new blood test could reveal: patients in the highest-risk group had roughly a 63 percent chance of a serious kidney event within 10 years, compared with only about 3 percent for those in the lowest-risk group, a far starker separation than existing tools could achieve. The score's accuracy held up strongly when tested in two independent groups of patients from different studies, suggesting the findings are not a fluke of the original dataset. Notably, the individual proteins making up the score were also linked to physical scarring and injury inside kidney tissue itself, lending biological credibility beyond its statistical performance. This kind of tool matters because carrying the high-risk gene variants alone does not reliably indicate who will develop kidney failure, leaving patients and doctors without a clear way to decide who needs closer monitoring or earlier treatment. The findings also have direct relevance to emerging drugs designed to counteract the effects of this gene, since accurately identifying likely progressors could ensure treatments are tested in, and eventually given to, the patients most likely to benefit, while sparing others unnecessary intervention. Because kidney failure disproportionately affects people of African ancestry, largely due to this genetic factor, the authors conclude that this proteomic score offers a practical tool for earlier identification of high-risk individuals, more efficient clinical trials, and a path toward narrowing long-standing racial disparities in kidney disease outcomes.